RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0037-1616761
Bemiparin and Fluid Flow Modulate the Expression, Activity and Release of Tissue Factor Pathway Inhibitor in Human Endothelial Cells In Vitro
Publikationsverlauf
Received
22. Januar 2001
Accepted after resubmission
28. August 2001
Publikationsdatum:
12. Dezember 2017 (online)
Summary
We investigated the localisation, gene expression, and activity of tissue factor pathway inhibitor (TFPI) in endothelial cells (EC) grown in static conditions or under shear stress, in the presence of unfractionated heparin (UFH) and two low-molecular-weight heparins (LMWHs), dalteparin and bemiparin (a second generation of LMWHs). All three preparations induced increased release, cellular redistribution, and enhanced activity of TFPI on the cell surface in static EC. In EC grown under shear stress (0.27, 4.1 and 19 dyne/cm2) and incubated with each heparin for 24 h, the release of TFPI was significantly correlated with the level of flow for bemiparin and dalteparin, but not for UFH. For all three levels of flow tested, bemiparin induced the highest secretion and increase of both cellular TFPI and cell surface activity of the inhibitor. The expression of TFPI mRNA, determined by Northern blotting, was specifically modulated by heparins. All three preparations increased the expression of TFPI by 60 to 120% in EC under minimal flow, but only bemiparin enhanced TFPI mRNA in EC under the arterial flow. Immunogold electron microscopy revealed that EC exhibited strong cellular labelling for TFPI when grown under arterial flow in the presence of bemiparin. We conclude that in EC subjected to shear stress in vitro bemiparin is more efficient than UFH or dalteparin in modulating the expression, release and activity of TFPI. We therefore suggest that bemiparin may be superior over the conventional heparins in maintaining the anticoagulant properties of the endothelium.
-
References
- 1 Gimbrone Jr. MA, Nagel T, Topper JN. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest 1997; 99: 1809-13.
- 2 Gimbrone Jr. MA. Endothelial dysfunction, hemodynamic forces and atherosclerosis. Thromb Haemost 1999; 82: 722-6.
- 3 Taubman MB, Fallon JT, Schecter AD, Giesen PLA, Mendlowitz M, Fyfe BS, Marmur JD, Nemerson Y. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997; 78: 200-4.
- 4 Westmuckett AD, Lupu C, Goulding DA, Das S, Kakkar VV, Lupu F. In situ analysis of tissue factor-dependent thrombin generation in human atherosclerotic vessels. Thromb Haemost 2000; 84: 904-11.
- 5 Giesen PLA, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
- 6 Leatham EW, Bath PMW, Tooze JA, Camm AJ. Increased monocyte tissue factor expression in coronary disease. Br Heart J 1995; 73: 10-3.
- 7 Marsh Lyle E, Lewis SD, Lehman ED, Gardell SJ, Motzel SL, Lynch Jr. JJ. Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis. Thromb Haemost 1998; 79: 656-62.
- 8 Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J. Low molecular weight heparin and prevention of postoperative deep vein thrombosis. Brit Med J 1982; 284: 375-9.
- 9 Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 1994; 24: 105-17.
- 10 McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vasc Biol 1996; 16: 1285-91.
- 11 Broze Jr. GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
- 12 Crawley J, Lupu F, Westmuckett AD, Severs NJ, Kakkar VV, Lupu C. Expression, localization and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000; 20: 1362-73.
- 13 Lupu C, Kruithof EKO, Kakkar VV, Lupu F. Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons. Thromb Haemost 1999; 82: 1652-8.
- 14 Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908-13.
- 15 Rao LV, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 121-9.
- 16 Sandset PM, Bendz B, Hansen J-B. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 2000; 30 (Suppl. 02) 48-56.
- 17 Hansen J-B, Sandset PM, Huseby KR, Huseby N-E, Bendz B, Ostergaard P, Nordoy A. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Brit J Haematol 1998; 101: 638-46.
- 18 Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative, double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. Thromb Haemost 2000; 83: 523-9.
- 19 Westmuckett AD, Lupu C, Roquefeuil S, Krausz T, Kakkar VV, Lupu F. Fluid flow induces upregulation of synthesis and release of tissue factor pathway inhibitor in vitro. Arterioscler Thromb Vasc Biol 2000; 20: 2474-82.
- 20 Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999; 19: 2251-62.
- 21 Lupu C, Goodwin CA, Westmuckett AD, Emeis JJ, Scully MF, Kakkar VV, Lupu F. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae: regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol 1997; 17: 2964-74.
- 22 Sevinsky JR, Rao LV, Ruf W. Ligand-induced protease receptor trans-location into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996; 133: 293-304.
- 23 Ott I, Miyagi Y, Miyazaki K, Heeb MJ, Mueller BM, Rao LVM, Ruf W. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2000; 20: 874-82.
- 24 Redmond EM, Cahill PA, Sitzmann JV. Perfused transcapillary smooth muscle and endothelial cell co-culture – a novel in vitro model. In Vitro Cell Dev Biol Anim 1995; 31: 601-9.
- 25 Lipowsky HH. Shear stress in the circulation. In: Flow-Dependent Regulation of Vascular Function. Bevan JA, Kaley G, Rubanyi GM. eds. Oxford, UK: Oxford University Press; 1995: 28-45.
- 26 Black SC, Gralinski MR, Friedrich GS, Kilgore KS, Driscoll EM, Lucchesi BR. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischemic and reperfusion injury. Cardiovasc Res 1995; 29: 629-36.
- 27 Lantieri LA, Ozbek MR, Deune EG, Ornberg RL, Brown DM, Chung SH, Wun T-C, Cooley BC, Khouri RK. Prevention of microvascular thrombosis by topical application of recombinant tissue factor pathway inhibitor. Plast Reconstr Surg 1996; 97: 587-93.
- 28 Ernoffson M, Strekerud F, Toss H, Abidgaard U, Wallentin L, Siegbahn A. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998; 79: 491-4.
- 29 Glagov S, Zarins C, Giddens DP, Ku DN. Hemodynamics and atherosclerosis: insights and perspectives gained from studies of human arteries. Arch Pathol Lab Med 1988; 112: 1018-31.